CAC
SMMT icon

Cowen and Company’s Summit Therapeutics SMMT Stock Holding History

Cowen and Company’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$311K – 266
2024
Q3 		$311K Hold
25,000
– – 0.01% 202
2024
Q2 		$47.5K Buy
+25,000
New +$135K ﹤0.01% 323

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Cowen and Company's SMMT Position: Q4 2022 in Review

Cowen and Company sold out of Summit Therapeutics (SMMT) in Q4 2022, closing a stake of 17,249 shares — an estimated $21K sold.

Cowen and Company first reported a position in SMMT in Q2 2022 and held it in 2 quarters. The position peaked at $21K in Q3 2022. 61 funds tracked by Wall St. Rank hold SMMT as of Q4 2022.

  • Cowen and Company reported no remaining Summit Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 17,249 Summit Therapeutics shares in Q4 2022, an estimated $21K.
  • Cowen and Company first reported a position in Summit Therapeutics in Q2 2022 and held it in 2 quarters.
  • Cowen and Company's Summit Therapeutics position peaked at $21K in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.